Marijuana Abuse Clinical Trial
Official title:
Effects of Stress and Drug-cue Exposure on Craving and Marijuana Seeking Behavior in Regular Cannabis Smokers
Verified date | April 2024 |
Source | Wayne State University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the proposed study to examine the links among stress, craving for marijuana, and marijuana reminders, or "cues". In this study, an agent called yohimbine will be used to produce stress-like responses. Yohimbine is known to cause stress response in studies of alcohol and other substance use disorders. This study intends to show it can be used to cause stress in marijuana users as well.
Status | Completed |
Enrollment | 12 |
Est. completion date | October 27, 2023 |
Est. primary completion date | October 27, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 55 Years |
Eligibility | Inclusion Criteria: - Participants (18-55 yr) will be current marijuana users, based on self-report and THC-positive urine samples. - Candidates must meet DSM-5 criteria for Mild-to-Moderate Cannabis Use Disorder (CUD) and be willing to participate in research but not seeking treatment. - Candidates must be in good health, as assessed using data from psychiatric evaluation, extensive substance use history interview, and medical evaluations including medical history, physical exam, standard lab tests and 12-lead ECG. Exclusion Criteria: Candidates with the following conditions will be excluded: - Serious psychiatric illness (e.g. psychotic or bipolar disorder, recent suicide attempts, major depression). - Substance Use Disorders other than Cannabis or Nicotine Use Disorders and Mild Alcohol Use Disorder. - Neurological diseases - Cardiovascular problems (e.g. including systolic BP >140 or <95 mmHg, diastolic BP >90 mmHg, abnormal ECG). - Pulmonary diseases - Systemic diseases - Cognitive impairment (<80 IQ) - Past-month medications that increase study risk. - Women who are pregnant, lactating, or if heterosexually active and not using medically approved birth control. - Candidates seeking Substance Use Disorder treatment. - Individuals unable to give voluntary informed consent will be excluded. |
Country | Name | City | State |
---|---|---|---|
United States | Tolan Park Medical Building | Detroit | Michigan |
Lead Sponsor | Collaborator |
---|---|
Wayne State University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Marijuana Craving Visual Analog Scale (VAS) (Self-report measure) | Change is being assessed. Marijuana Craving VAS administered at baseline 0900. It will then be administered at 1000, 1030, 1100, 1200, 1220, 1245, 1300, 1315, 1345. | ||
Primary | Marijuana Craving Questionnaire (Self-report measure) | Change is being assessed. Marijuana Craving Quest.administered at baseline 0900. It will then be administered at 1000, 1030, 1100, 1200, 1410, 1430, 1500, 1530, 1600, 1630. | ||
Primary | Questionnaire of Smoking Urges (Self-report measure) | Change is being assessed. Questionnaire is administered at baseline 0900. It will then be administered at 1000, 1030, 1100, 1200, 1410, 1430, 1500, 1530, 1600, 1630. | ||
Primary | Marijuana Rating Form (Self-report measure) | Change is being assessed. Marijuana Rating Form is administered 30 minutes after each smoking episode in the sampling session. | ||
Primary | Marijuana Withdrawal Checklist | Change is being assessed. Questionnaire is administered every morning and evening. | ||
Primary | Subjective Effects Scale Visual Analog Scale (VAS) (Self-report measure) | Change is being assessed. Subjective Effects Scale administered at baseline 0900.It will then be administered at 1000, 1030, 1100, 1200, 1410, 1430, 1500, 1530, 1600, 1630. | ||
Primary | Positive & Negative Affect Schedule (Self-report measure) | Change is being assessed. Questionnaire is administered at baseline 0900. It will then be administered at 1000, 1030, 1100, 1200, 1410, 1430, 1500, 1530, 1600, 1630. | ||
Primary | Systolic blood pressure (physiological effects) | Change is being assessed. Systolic blood pressure measured at baseline 0900. It will then be measure at 1000, 1030, 1100, 1200, 1410, 1430, 1500, 1530, 1600, 1630. | ||
Primary | Diastolic blood pressure (physiological effects) | Change is being assessed. Diastolic blood pressure measured at baseline 0900. It will then be measure at 1000, 1030, 1100, 1200, 1410, 1430, 1500, 1530, 1600, 1630. | ||
Primary | Heart rate (physiological effects) | Change is being assessed. Heart rate measured at baseline 0900. It will then be measure at 1000, 1030, 1100, 1200, 1410, 1430, 1500, 1530, 1600, 1630. | ||
Primary | Core-body temperature (physiological effects) | Change is being assessed. Core-body temperature measured at baseline 0900. It will then be measure at 1000, 1030, 1100, 1200, 1410, 1430, 1500, 1530, 1600, 1630. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01539525 -
Screening to Augment Referral to Treatment- Project START
|
Phase 2 | |
Completed |
NCT00158249 -
Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals
|
Phase 2 | |
Completed |
NCT00842985 -
Dronabinol Interactions in Humans
|
N/A | |
Completed |
NCT00484302 -
Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis
|
N/A | |
Completed |
NCT00218478 -
Evaluating Responses to Drug-Related Cues Versus Neutral Cues to Understand the Effects of Marijuana Craving - 1
|
Phase 1 | |
Completed |
NCT00227903 -
Therapeutic Substance Abuse Treatment in Pregnancy - 1
|
Phase 2 | |
Completed |
NCT00227864 -
A Brief Marijuana Intervention for Adolescent Women - 1
|
Phase 3 | |
Completed |
NCT00249509 -
Effectiveness of Nefazodone and Bupropion in Treating Marijuana Dependent Individuals
|
Phase 2 | |
Completed |
NCT03717272 -
Effect of AEF0117 on Subjective Effects of Cannabis in CUD Subjects
|
Phase 2 | |
Completed |
NCT00142961 -
Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder
|
Phase 2 | |
Terminated |
NCT02102230 -
CBT-I for Cannabis Use
|
N/A | |
Completed |
NCT00580671 -
Treatment for Adolescent Marijuana Abuse
|
N/A | |
Completed |
NCT00360269 -
Atomoxetine Treatment for ADHD and Marijuana Dependence
|
Phase 2 | |
Completed |
NCT00227916 -
Motivational Interviews for Incarcerated Teens - 1
|
N/A | |
Active, not recruiting |
NCT05322941 -
Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD)
|
Phase 2 | |
Completed |
NCT02797990 -
Conflict Between Maternal Autonomy and Child Health in Substance-use
|
N/A | |
Completed |
NCT01762696 -
A Real-time, Contextual Intervention Using Mobile Technology to Reduce Marijuana Use in Youth
|
N/A | |
Completed |
NCT03154580 -
Marijuana Cue-Reactivity & Seeking Behavior in Regular Cannabis Users
|
Phase 1 | |
Completed |
NCT00217971 -
Dronabinol Treatment for Marijuana Addiction
|
Phase 2 | |
Completed |
NCT00218517 -
Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1
|
Phase 2 |